Preview Mode Links will not work in preview mode

This Week in Cardiology

Sep 17, 2021

Cardiac arrest care, finerenone, carotids, meds post TAVI: less is more and the new may not be as grand as the tried and true. John Mandrola, MD, provides a third ESC review. To read a partial transcript or to comment, visit:

I - Cardiac Arrest Care

- Angiography Can Wait for Cardiac Arrest Without ST-Elevation

- Angiography after Out-of-Hospital Cardiac Arrest without ST-Segment Elevation

- Coronary Angiography after Cardiac Arrest without ST-Segment Elevation

II - Finerenone

- FIDELITY: Finerenone Cuts CV Risk in T2D Across CKD Spectrum

- Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes

- Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes

III - Carotid Intervention

- ACST-2: Carotid Stenting, Surgery on Par in Asymptomatic Patients

- Second asymptomatic carotid surgery trial (ACST-2): a randomised comparison of carotid artery stenting versus carotid endarterectomy


- 'Less Is More' for Edoxaban in Post-TAVI Anticoagulation: ENVISAGE-TAVI AF

- Edoxaban versus Vitamin K Antagonist for Atrial Fibrillation after TAVR

- ATLANTIS Hints at How to Choose Post-TAVR Antithrombotics

- A Controlled Trial of Rivaroxaban after Transcatheter Aortic-Valve Replacement


- What Are the Implications of ACST-2 for Patients With Asymptomatic Carotid Stenosis?

- Top 5 Studies From ESC 2021

You may also like:

Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine

The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD

Questions or feedback, please contact